Electroconvulsive therapy (ECT) for depressive illness, schizophrenia, catatonia and mania
... The economic model for depression was based on a severely depressed population requiring hospitalisation. As clinical opinion differs to whether ECT should be used only as a last resort treatment or whether it could be used earlier in the treatment hierarchy the model was constructed to allow the ev ...
... The economic model for depression was based on a severely depressed population requiring hospitalisation. As clinical opinion differs to whether ECT should be used only as a last resort treatment or whether it could be used earlier in the treatment hierarchy the model was constructed to allow the ev ...
Self-Reported Depressive Symptoms and Antisocial
... role of family support in buffering adolescents against depressive symptoms and antisocial behaviour. Concurrent comorbidity between self-reported depressive symptoms and antisocial behaviour in cross-sectional study design was high in both sexes, as adolescents displaying antisocial behaviour had a ...
... role of family support in buffering adolescents against depressive symptoms and antisocial behaviour. Concurrent comorbidity between self-reported depressive symptoms and antisocial behaviour in cross-sectional study design was high in both sexes, as adolescents displaying antisocial behaviour had a ...
As a PDF file - E
... Suicidal behaviour – suicidal ideation, suicide attempt and completed suicide – probably represents a continuum of self-harming behaviours. Suicidal behaviour as a concept includes the tendency, thoughts or acts of self-harming behaviour or life-threatening risks. Suicidal behaviour can be direct – ...
... Suicidal behaviour – suicidal ideation, suicide attempt and completed suicide – probably represents a continuum of self-harming behaviours. Suicidal behaviour as a concept includes the tendency, thoughts or acts of self-harming behaviour or life-threatening risks. Suicidal behaviour can be direct – ...
Clinical Practice Guideline on Major Depression in Childhood
... One of the priorities of the Ministry of Health and Social Policy is to decrease unjustified clinical variability, thereby helping to make the most appropriate decisions based on the best existing knowledge. The healthcare practice is increasingly more complex due to a multitude of factors, one of t ...
... One of the priorities of the Ministry of Health and Social Policy is to decrease unjustified clinical variability, thereby helping to make the most appropriate decisions based on the best existing knowledge. The healthcare practice is increasingly more complex due to a multitude of factors, one of t ...
Evidence-based guidelines for treating depressive
... order to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in September 2012. Key areas in treating depression were reviewed and the strength of evidence and clinical implications ...
... order to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in September 2012. Key areas in treating depression were reviewed and the strength of evidence and clinical implications ...
1 Selective serotonin reuptake inhibitors (SSRI) – sales, withdrawal
... The first two studies led to the third study about the drug authorities’ reactions to benzodiazepine dependence and SSRI withdrawal syndrome and the way drug authorities informed the health professionals and the public about possible adverse reactions. It seems reasonable to explore how drug author ...
... The first two studies led to the third study about the drug authorities’ reactions to benzodiazepine dependence and SSRI withdrawal syndrome and the way drug authorities informed the health professionals and the public about possible adverse reactions. It seems reasonable to explore how drug author ...
The World Federation of Societies of Biological Psychiatry (WFSBP
... been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (A–F). As these guide ...
... been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (A–F). As these guide ...
Evidence-based pharmacotherapy of panic
... advised given the increase in blood pressure that is sometimes observed. In TCAs the most commonly reported side-effects in panic disorder patients are anticholinergic effects, increased sweating, sleep disturbance, orthostatic hypotension and dizziness, fatigue and weakness, cognitive disturbance, we ...
... advised given the increase in blood pressure that is sometimes observed. In TCAs the most commonly reported side-effects in panic disorder patients are anticholinergic effects, increased sweating, sleep disturbance, orthostatic hypotension and dizziness, fatigue and weakness, cognitive disturbance, we ...
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision Guidelines
... I: Evidence from meta-analysis of randomised controlled trials*, at least one large, good quality, randomised controlled trial* or replicated, smaller, randomised controlled trials* II: Evidence from small, non-replicated, randomised controlled trials*, at least one controlled study without randomis ...
... I: Evidence from meta-analysis of randomised controlled trials*, at least one large, good quality, randomised controlled trial* or replicated, smaller, randomised controlled trials* II: Evidence from small, non-replicated, randomised controlled trials*, at least one controlled study without randomis ...
MDMA-assisted psychotherapy - Multidisciplinary Association for
... a different modality (may need to be) selected as in …a patient who is too overwhelmed by anxiety to tolerate exposure therapy…. There are limited data to guide the clinician in the treatment of patients with treatment resistant PTSD” ...
... a different modality (may need to be) selected as in …a patient who is too overwhelmed by anxiety to tolerate exposure therapy…. There are limited data to guide the clinician in the treatment of patients with treatment resistant PTSD” ...
World Federation of Societies of Biological Psychiatry (WFSBP)
... venlafaxine are slightly more effective than SSRI in severely depressed hospitalized patients. Antidepressants differ considerably in their side-effects profile, potential for interacting with other drugs and in the danger they pose when taken in overdose. Second (e.g., bupropion, maprotiline, mians ...
... venlafaxine are slightly more effective than SSRI in severely depressed hospitalized patients. Antidepressants differ considerably in their side-effects profile, potential for interacting with other drugs and in the danger they pose when taken in overdose. Second (e.g., bupropion, maprotiline, mians ...
Atypical Depression in the 21st Century: Diagnostic and
... Similar findings were obtained by Quitkin and colleagues55 in an RCT of 90 outpatients with atypical depression. They observed response rates of 83%, 50%, and 19% for phenelzine, imipramine, and placebo, respectively. In this study, the difference in response rate between phenelzine and imipramine w ...
... Similar findings were obtained by Quitkin and colleagues55 in an RCT of 90 outpatients with atypical depression. They observed response rates of 83%, 50%, and 19% for phenelzine, imipramine, and placebo, respectively. In this study, the difference in response rate between phenelzine and imipramine w ...
307 Post Traumatic S.. - University Psychiatry
... FDA approval for sertraline (’99), paroxetine (’01) Maintenance efficacy established for sertraline for up to 52 weeks (Davidson et al. ‘01) Improvement in all 3 sx clusters and QOL measures, treatments safe ...
... FDA approval for sertraline (’99), paroxetine (’01) Maintenance efficacy established for sertraline for up to 52 weeks (Davidson et al. ‘01) Improvement in all 3 sx clusters and QOL measures, treatments safe ...
View/Open - Victoria University of Wellington
... results compared to placebo for drug approval, no evidence is required that a new drug is superior to any existing drugs, and data from unsuccessful trials need not be lodged with the FDA (Medawar, Hardon, & Herzheimer, 2004). The overall impression conveyed to researchers, physicians, and patients, ...
... results compared to placebo for drug approval, no evidence is required that a new drug is superior to any existing drugs, and data from unsuccessful trials need not be lodged with the FDA (Medawar, Hardon, & Herzheimer, 2004). The overall impression conveyed to researchers, physicians, and patients, ...
Suicidal Behaviour in Children and Adolescents. Part 1
... United Kingdom, failed to find a positive relation between SSRI prescription and suicide rates.^** Despite these encouraging trends, there has been increased concern that SSRIs and other antidepressants can paradoxically increase suicidal ideation in children and adolescents with depression. In 2003 ...
... United Kingdom, failed to find a positive relation between SSRI prescription and suicide rates.^** Despite these encouraging trends, there has been increased concern that SSRIs and other antidepressants can paradoxically increase suicidal ideation in children and adolescents with depression. In 2003 ...
The Risks and Benefits of Selective Serotonin Reuptake Inhibitors
... lists. Further articles were excluded due to lack of relevance of subject matter. To ensure studies met research criteria, articles of most interest were on childhood anxiety disorders and compliance on SSRI drug therapy. Citations from each article were analyzed and articles that pertained to the ...
... lists. Further articles were excluded due to lack of relevance of subject matter. To ensure studies met research criteria, articles of most interest were on childhood anxiety disorders and compliance on SSRI drug therapy. Citations from each article were analyzed and articles that pertained to the ...
The copycat phenomenon after two Finnish school shootings: an
... Methods: The nation-wide study evaluated 77 13- to 18-year-old adolescents who were sent for adolescent psychiatric evaluations between 8.11.2007 and 30.6.2009, one of the reasons for evaluation being a threat of massacre at school. The medical files of the copycats were retrospectively analysed usi ...
... Methods: The nation-wide study evaluated 77 13- to 18-year-old adolescents who were sent for adolescent psychiatric evaluations between 8.11.2007 and 30.6.2009, one of the reasons for evaluation being a threat of massacre at school. The medical files of the copycats were retrospectively analysed usi ...
View Full Page PDF - The British Journal of Psychiatry
... test was used to compare the time to relapse curves for the fluoxetine/fluoxetine and fluoxetine/placebo treatment groups. Analyses of change from baseline (week 12 of acute treatment) in TOP–8, MADRS, DTS, SCI–90–R, CGI–S and HRSA scores were conducted using a repeated-measures model with visit, tr ...
... test was used to compare the time to relapse curves for the fluoxetine/fluoxetine and fluoxetine/placebo treatment groups. Analyses of change from baseline (week 12 of acute treatment) in TOP–8, MADRS, DTS, SCI–90–R, CGI–S and HRSA scores were conducted using a repeated-measures model with visit, tr ...
Fluoxetine therapy in depersonalisation disorder: randomised controlled trial
... one who did not return, without explanation (CGI–I 1). Withdrawals from the placebo group were individually accounted for as follows: two persons before week 2, one because of work schedule and one without an explanation; and two persons by week 4, one because of work schedule (CGI–I 4) and one non- ...
... one who did not return, without explanation (CGI–I 1). Withdrawals from the placebo group were individually accounted for as follows: two persons before week 2, one because of work schedule and one without an explanation; and two persons by week 4, one because of work schedule (CGI–I 4) and one non- ...
Suicide risk in civilian PTSD patients
... SE = 0.085, p = 0.032, Exp(B) = 1.2] and receiving psychotropic medication [B = 2.37, SE = 1.098, p = 0.031, Exp(B) = 10.64] were significantly predictive of planned or attempted suicide. The odds of having plans or attempts to commit suicide compared to no suicidal ideation were 5.75 times higher f ...
... SE = 0.085, p = 0.032, Exp(B) = 1.2] and receiving psychotropic medication [B = 2.37, SE = 1.098, p = 0.031, Exp(B) = 10.64] were significantly predictive of planned or attempted suicide. The odds of having plans or attempts to commit suicide compared to no suicidal ideation were 5.75 times higher f ...
Antidepressant switching
... This regimen may be suitable if the first antidepressant has been taken for less than six weeks, and is therefore unlikely to cause discontinuation symptoms or if severe side effects with the first antidepressant have occurred. Abrupt cessation may also be acceptable when switching to a drug with a ...
... This regimen may be suitable if the first antidepressant has been taken for less than six weeks, and is therefore unlikely to cause discontinuation symptoms or if severe side effects with the first antidepressant have occurred. Abrupt cessation may also be acceptable when switching to a drug with a ...
suicidal-behavior in-adolescents
... • This is greater than the prevalence of substance abuse seen with any other psychiatric conditions, including schizophrenia, panic disorder, dysthymia and unipolar depression • Comorbid substance use increases the risk for suicide in ...
... • This is greater than the prevalence of substance abuse seen with any other psychiatric conditions, including schizophrenia, panic disorder, dysthymia and unipolar depression • Comorbid substance use increases the risk for suicide in ...
Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute
... Background: We tested whether transcranial magnetic stimulation (TMS) over the left dorsolateral prefrontal cortex (DLPFC) is effective and safe in the acute treatment of major depression. Methods: In a double-blind, multisite study, 301 medication-free patients with major depression who had not ben ...
... Background: We tested whether transcranial magnetic stimulation (TMS) over the left dorsolateral prefrontal cortex (DLPFC) is effective and safe in the acute treatment of major depression. Methods: In a double-blind, multisite study, 301 medication-free patients with major depression who had not ben ...
Comorbidity With ADHD Decreases Response to Pharmacotherapy
... 17 reports for inclusion in the metaanalysis. To be significant for the metaanalysis, trials had to report treatment response in samples of children and adolescents with BD where comorbidity with ADHD was systematically addressed. Clinical-outcome data had to be available on treatment response accor ...
... 17 reports for inclusion in the metaanalysis. To be significant for the metaanalysis, trials had to report treatment response in samples of children and adolescents with BD where comorbidity with ADHD was systematically addressed. Clinical-outcome data had to be available on treatment response accor ...
Generalized Anxiety Disorder
... conditions should be Included in the differential diagnosis for GAD ...
... conditions should be Included in the differential diagnosis for GAD ...
Study 329
Study 329 was a clinical trial conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant marketed as Paxil and Seroxat, in treating depressed teenagers. Paroxetine was released in 1991 by the British pharmaceutical company SmithKline Beecham, known since 2000 as GlaxoSmithKline (GSK). The drug made $11.6 billion between 1997 and 2006.Led by Martin Keller, then professor of psychiatry at Brown University, study 329 became controversial when it was discovered that the article in which the trial results were reported – published in 2001 in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) – had downplayed the trial's negative findings and had been ghostwritten by a PR firm hired by SmithKline Beecham. The controversy led to several lawsuits and strengthened calls for drug companies to disclose all their clinical research data. New Scientist wrote in 2015: ""You may never have heard of it, but Study 329 changed medicine.""The study, which compared paroxetine with imipramine, a tricyclic antidepressant marketed as Tofranil, failed to show efficacy for paroxetine in adolescent depression, something SmithKline Beecham acknowledged internally in 1998. In addition there were more examples of suicidal thinking and behaviour in the group taking paroxetine. Although the article included these negative results, it did not account for them in its conclusion. On the contrary, it concluded that paroxetine is ""generally well tolerated and effective for major depression in adolescents."" The company relied on the article to promote paroxetine for off-label use in teenagers.In 2003 Britain's Medicines and Healthcare Products Regulatory Agency (MHRA) analysed study 329 and other GSK studies of paroxetine. It concluded that there was no evidence of paroxetine's efficacy and a clear increase in suicidal behaviour in teenagers using it. The following month the MHRA and US Food and Drug Administration (FDA) advised doctors not to prescribe paroxetine to the under-18s. The MRHA launched a criminal inquiry into GSK's conduct, but announced in 2008 that there would be no charges. In 2004 New York State Attorney Eliot Spitzer sued GSK for having withheld the data. In 2012 the US Justice Department fined the company $3 billion, including a sum for withholding data on paroxetine, unlawfully promoting it for the under-18s, and preparing a misleading article about study 329.The JAACAP article on study 329 was never retracted. The journal's editors say the negative findings are included in a table, and that therefore there are no grounds to withdraw it. In September 2015 the BMJ published a re-analysis of study 329's data. This concluded that neither paroxetine nor imipramine had differed in efficacy in treating depression from placebo (an inert pill), that the paroxetine group had experienced more suicidal ideation and behaviour, and that the imipramine group had experienced more cardiovascular problems.